FAQ/Help |
Calendar |
Search |
Today's Posts |
|
02-08-2010, 11:39 AM | #1 | |||
|
||||
Senior Member
|
Not sure that anyone has posted this info on PDOR. The summit generated what looks to be like an intense discussion and I'd say that the key words or ideas center on biomarkers and the FDA hurdles involved in proving "disease modification" (inadequate measure in placebo controls).
Interestingly, Franz Hefti of Avid Pharmaceuticals comments on the 'druggability' of alpha-synuclein as a viable treatment concluded with some interesting statements on how a clinical trial might look like; I like that there is a clear drive or mandate to move beyond dopa and placebo measures. Alpha Synuclein MJFF Summary and Outcomes Some key things that were said about what a potential Alpha clinical trial might look like: • High hurdle for doing trials in non-symptomatic “patients”. • FDA approves drugs “for the treatment of Parkinson’s disease” based on difference to placebo in controlled trials. • “Disease modification” is not necessary for approval, thus the hurdle for such a specific claim in the label is high. • Differences in rates of progression are not sufficient • A claim for ‘disease modification’ must be forced on the FDA • based on disease mechanism data (incl. surrogate markers) • example: current discussions on anti-A therapy in AD Clinical trials using behavior and dopaminergic neuron degeneration as outcome measures long and costly • Seek alternative outcome measures which reflect -synuclein-related pathology more directly than dopaminergic neuron degeneration Glad to see that their concerns echo what we have been voicing. One thing I'm wondering...is alpha-synuclein treatment being targeted for early (pre-motor) symptom PD only, or might we all benefit from it? There seems to be a big focus on how they could treat asymptomatic (pre-motor symptoms) and the need for biomarkers? Laura |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Overexpression of Alpha Synuclein and ER-gogli trafficking | Parkinson's Disease | |||
alpha synuclein/PD link in the news again | Parkinson's Disease | |||
Alpha synuclein news | Parkinson's Disease | |||
Curcumin inhibits alpha-synuclein | Parkinson's Disease | |||
MJFF: Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain | Parkinson's Disease |